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ABSTRACT
Ovol1 belongs to a family of evolutionarily
conserved zinc finger proteins that act downstream
of key developmental signaling pathways such as
Wnt and TGF-b/BMP. It plays important roles in
epithelial and germ cell development, particularly by
repressing c-Myc and Id2 genes and modulating
the balance between proliferation and differentia-
tion of progenitor cells. In this study, we show that
Ovol1 negatively regulates its own expression
by binding to and repressing the activity of its
promoter. We further demonstrate that Ovol1 uses
both passive and active repression mechanisms to
auto-repress: (1) it antagonizes transcriptional
activation of c-Myb, a known positive regulator
of proliferation, by competing for DNA binding;
(2) it recruits histone deacetylase activity to the
promoter via an N-terminal SNAG repressor
domain. At Ovol1 cognate sites in the endogenous
Ovol1 promoter, c-Myb binding correlates with
increased histone acetylation, whereas the expres-
sion of Ovol1 correlates with a displacement of
c-Myb from the DNA and decreased histone
acetylation. Collectively, our data suggest that
Ovol1 restricts its own expression by counteracting
c-Myb activation and histone acetylation of the
Ovol1 promoter.
INTRODUCTION
The evolutionarily conserved ovo genes encode C2H2 zinc
ﬁnger transcription factors and act downstream of
Wg(Wnt)/b-catenin and TGF-b/BMP signaling pathways
that have been widely implicated in normal and malignant
development of myriad tissues (1,2). Functional studies
in several organisms have demonstrated an involvement
of ovo genes in the development and diﬀerentiation
of a number of epithelial lineages (2–7). However,
less progress has been made on the biochemical mechan-
ism by which Ovo proteins function to regulate gene
expression in these biological processes.
Ovol1 is expressed in the epithelial tissues of hair
follicles, interfollicular epidermis, kidney, as well as in the
male germinal epithelium (7). In these tissues, Ovol1
expression correlates with the onset of terminal diﬀer-
entiation of progenitor cells (7–9). Ovol1 knockout
mice display pleiotropic defects including ruﬄed hairs,
a hyperproliferative epidermis, defective spermatogenesis
and cystic kidneys (7–10). A common theme of Ovol1
function appears to be promoting the transition from
a proliferating, less diﬀerentiated state to a post-mitotic,
more diﬀerentiated state. In epidermis, Ovol1 is required
for embryonic epidermal progenitor cells to eﬃciently exit
proliferation to embark on the terminal diﬀerentiation
process (9). During spermatogenesis, Ovol1 is required
for germ cells to exit from mitosis and enter meiosis (8).
Ovol1 likely plays a similar role in kidney epithelial cells,
as it is known that over-proliferation of these cells
results in kidney cyst formation (11). Three downstream
targets of Ovol1 have been identiﬁed: c-Myc, Id2 and
Ovol2 (8–10). These genes are expressed in proliferating
progenitor cells and their expression is up-regulated
when Ovol1 is deleted. Both c-Myc and Id2 are known
to have pro-proliferation and/or anti-diﬀerentiation
roles, and therefore their negative regulation by Ovol1
is consistent with the growth inhibitory function of
Ovol1 (8,9).
Feedback control is common for important regulators
of development. Genetic evidence suggests that
Drosophila ovo auto-regulates (12,13), underlying the
importance of an intricate regulation of ovo gene
expression. This raises the interesting possibility that
Ovol1 might be a target of transcriptional repression by
its own gene product. Distinct from Drosophila ovo
and mouse Ovol2, which encode multiple protein
isoforms with either transcriptional activator or repressor
activity (14–16), Ovol1 encodes a single polypeptide with
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we address whether Ovol1 represses its own expression
and how it represses transcription at a mechanistic level.
The predominant mode of action of a sequence-speciﬁc
DNA-binding transcriptional repressor in eukaryotes is to
recruit co-repressor complexes to its target promoters
(active repression). Many sequence-speciﬁc repressors
recruit histone deacetylases (HDACs), either directly or
via adaptor proteins such as Sin3 [reviewed in (17,18)].
HDACs, opposing the function of histone acetylases,
catalyze the deacetylation of lysine residues of core
histone tails. This results in a more compact chromatin
structure and consequently decreased accessibility for
transcription factors. Two of the class I HDACs, HDAC1
and HDAC2, have been most widely implicated in
transcriptional repression by myriad DNA-binding
repressors (19). Transcriptional repression can also
occur by a passive mechanism, where repressors interfere
with the function of transcriptional activators, for
example by competing for binding to common DNA
sequences [reviewed in (18,20)]. Does Ovol1 interact
biochemically or functionally with such repressors
or activators? Such insight will add to our overall
understanding of molecular pathways underlying the
control of epithelial cell proliferation and diﬀerentiation,
and might implicate additional potential players in this
important process. Here we provide evidence that Ovol1
negatively regulates its own expression by binding to and
repressing the Ovol1 promoter. We further demonstrate
that Ovol1 represses transcription using both passive
(competing with the c-Myb transcriptional activator,
a known positive regulator of proliferation) and active
(recruiting HDAC1) repression mechanisms.
MATERIALS AND METHODS
CASTing (cyclic amplification ofselected targets)
An 80-bp oligonucleotide was synthesized (IDT
Technologies), which contained 35-base random nucleo-
tides ﬂanked by sequences complementary to primers A
and B for cloning purposes. The sequences of these three
oligonucleotides are as follows: 80-base oligonucleotide,
50-GGATCCCTGCCTTCACCGAAGC(N)35TTGGGG
ACTATGAATTCCTGAGG-30; primer A, 50-GGATCC
CTGCCTTCACCGAAG-30; primer B, 50-CCTCAGGA
ATTCATAGTCCCC-30. A random sequence library of
double-stranded radiolabeled oligonucleotides was
prepared by annealing the 80-base oligonucleotide to
5-fold molar excess of primer B followed by extension
with Klenow. The extension reaction for the annealed
double-stranded oligonucleotide was performed in 50ml
of the labeling reaction mixture that contained 50mM
Tris-HCl (pH 7.5), 10mM MgCl2, 100mM each of dATP,
dGTP and dTTP and 5ml of 3000Ci/nmol of [a-
32P]-
dCTP. The labeling reaction mixture was incubated at
378C for 1h with 5 units of the Klenow enzyme
(Stratagene). The radiolabeled DNA was puriﬁed by
using G-50 Nick columns (Amersham) and subjected to
EMSA. EMSAs were performed by adding 100ng of
recombinant His6–Ovol1 protein (9) to DNA-binding
buﬀer (5% glycerol, 10mM HEPES, pH 7.9, 75mM KCl,
1mM DTT, 2.5mM MgCl2, 1mM EDTA, 1mM ZnCl2)
containing 0.5mg of poly (dA.dT), 5mg of bovine
serum albumin, and 10fmols of
32P-labeled probe.
The reaction was incubated at room temperature for
30min and the DNA–protein complexes were resolved by
electrophoresis through a non-denaturing 5% polyacry-
lamide gel in 1 Tris-borate-EDTA (TBE) buﬀer at 100V
for 3h. The complexes speciﬁcally formed in the presence
of His6–Ovol1 were detected by autoradiography, excised
from gels, and eluted overnight at 378C in DNA-elution
buﬀer containing 0.3M NaCl, 1mM EDTA and 0.1%
SDS. The eluted DNA was extracted once in phenol–
chloroform, and then precipitated with ethanol.
The puriﬁed DNA was subjected to PCR ampliﬁcation
with primers A and B in the presence of [a-
32P]-dCTP.
Ampliﬁcation was carried out by 20 cycles of denaturation
at 948C for 20s, annealing at 498C for 20s and extension
at 728C for 30s. The ampliﬁed DNA was puriﬁed using
G-50 Nick columns, and was used in subsequent EMSA
experiments. After four cycles of CASTing, the ﬁnal
ampliﬁed DNA was cloned directly using pCR2.1-TOPO
TA Cloning kit (Invitrogen). Nucleotide sequences of 105
independent clones were determined. The degenerate
portion of the sequences was compiled and analyzed
for shared sequence patterns by matrix-based pattern
discovery using the CONSENSUS program developed
by Jerry Hertz (web interface by Jacques van Helden;
http://rsat.ulb.ac.be/rsat).
Electrophoretic mobility shiftassay (EMSA)
The full-length and truncated Ovol1 proteins used for
EMSA assays were produced in bacteria (9) or by in vitro
transcription/translation reactions. Brieﬂy, 5mg of the
linearized DNA template for the transcription reaction
was generated by digesting the appropriate expression
plasmids overnight at 378C with BamHI. The linearized
DNA was then phenol-chloroform extracted and ethanol
precipitated. One microgram of the linearized DNA was
next incubated in 50ml of transcription mix containing
10mM DTT, 1mM rNTPs, 40 units of RNase inhibitor
RNAout (Promega) and T7 RNA polymerase for 1h at
378C. The transcribed RNA was isolated by phenol–
chloroform extraction and ethanol precipitation.
A portion of this RNA (3ml of the 50ml transcription
reaction) was next used in in vitro translation reaction
containing
35S-methionione to generate
35S-labeled
proteins. The translation reaction was performed in a
20-ml reaction volume using the rabbit reticulocyte lysate
system (Promega, Cat # L4960), exactly as per manufac-
turer’s instructions. One microliter of the translation
reaction was thereafter run on a 10% SDS-PAGE gel and
autoradiographed to ensure the generation of
35S-labeled
protein products of the appropriate molecular weights
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DNA-binding domain of chicken c-Myb was generated
as described (21,22), and used in the DNA-binding studies
because it displays a much higher aﬃnity for cognate sites
than the full-length protein (23). EMSA was performed
as described using 0.2–0.3 pmol of labeled oligonucleo-
tides and 0.05–2.5mg of recombinant His6–Ovol1,
or 1–3ml of the 20-ml translation reaction, or 1.5–3mg
of c-Myb-expressing bacterial extracts. The sequences
of c-Myb cognate oligonucleotides mim-A and mim-C
are 50-AGCGCTAAAAAACCGTTATAATGTGCA
GAT-30 and 50-GTTGATTTCCATCTGTTATTTGAG
CTAAG-30, respectively. The protein–DNA complexes
were resolved on 6% non-denaturing polyacrylamide gels
and visualized by autoradiography.
DNase I andhydroxyl radical footprinting
DNase I footprinting assay was performed using
a Sau3AI–BssHII fragment (position  356 to þ15)
of the Ovol1 promoter, labeled with
32P at the Sau3AI
end and 0.5–3mg of recombinant His6–Ovol1 protein
as described in (1). The Maxim–Gilbert reactions G, C
and CþT were used as molecular-weight markers.
Hydroxyl radical footprinting assay was performed as
described (24) in a volume of 200ml containing 20–30fmol
( 4 10
4cpm) of 50 P
32 single end-labeled Ovol1 promo-
ter fragment (position  356 to þ15) and 0.5–2mgo f
recombinant His6–Ovol1 protein. Speciﬁcally, protein–
DNA binding was for 20min at room temperature,
followed by treatment with hydroxyl radical for 5min
at room temperature, and ﬁnally quenched by the
addition of 20ml of 0.2M thiourea. Reaction products
were resolved by electrophoresis on a 10% denaturing
polyacrylamide gel containing 7M urea in TBE buﬀer
along with Maxim–Gilbert G, C and CþT reactions
on the same promoter fragment. Gels were scanned by
a phosphorimager and band intensities quantiﬁed.
Northern blot analysis
Total RNA was extracted from skin of Ovol1
 /  embryos
and control littermates, and northern analysis was
performed as described using an Ovol1 probe that
hybridizes to a 1-kb region at the 5 0of the cDNAs (7).
Reporter assays
Assays were performed in 293T and NIH3T3 cells.
The 293T cells were transfected using calcium phosphate
as described (25) and NIH3T3 cells using Polyfectene
(Qiagen). Typically, transfection experiments were done in
24-well plates with each well transfected with a total of
0.5mg of plasmids including 0.05mg of pGL3-Ovol1
[where Ovol1 promoter is cloned upstream of the
luciferase reporter; (1)] or 0.02mg of Gal-tk-luc (where
luciferase is under the control of a minimal tk promoter
downstream of Gal4-binding sites, or tk-luc control),
0.04mgo fb-actin-b-gal construct (transfection control),
varying amounts of Ovol1 expression constructs
(as indicated in ﬁgure legends), and murine c-Myb
expression vector (pEQP2-CMV-c-Myb) wherever
mentioned. pCB6þ or pCMX-GalDBD (empty vector
containing the CMV promoter) was used as ﬁller DNA.
In these and subsequent experiments, the amounts of
wild-type and mutant expression plasmids were stan-
dardized based on quantiﬁcation of protein levels by
Western blot analysis. Cells were harvested 48–60h after
transfection and luciferase activity was measured in whole
cell extracts using the Luciferase Assay System (Promega).
b-galactosidase activity was measured as previously
described (26). Transfection assay to study the eﬀect of
the HDAC inhibitor trichostatin A (TSA) was performed
by adding TSA 28h after transfection at a ﬁnal
concentration of 100ng/ml. Cells were collected 20h
later for luciferase and b-galactosidase analyses.
Immunoprecipitation (IP)
IP experiments were done using whole cell lysates from
293T cells seeded in 10-cm dishes and transfected with
8mg of pCB6-Ovol1 (or 1.6mgo f15-Ovol1, in which
the ﬁrst 15 amino acids were deleted) and 14mg
of Flag-tagged HDAC1,  2o r 3 (generous gifts of
Dr Edward Seto, H. Lee Moﬃtt Cancer Center and
Research Institute). To detect the interaction between
Ovol1 and endogenous HDAC1, 293T cells transfected
with 6mg of pCB6-Ovol1 were used. IP was performed as
described (27) using anti-Flag (Cat # F3165, Sigma)
or anti-Ovol1 (1) antibodies. Western blots were probed
with anti-Flag, anti-Ovol1, anti-HDAC1 (Cat #sc-7872,
Santa Cruz), or anti-HDAC3 (Cat # 05-813, Upstate)
antibodies.
Chromatin immunoprecipitation (ChIP)
NIH3T3 cells plated in 10-cm dishes were transfected with
either 8mg pCB6-Ovol1 (or 8mg 15), or 4mg pCB6-
Ovol1 (or 4mg ZnFC2A) and 8mg of a murine c-Myb
expression construct, or 8mg of the c-Myb expression
construct. Immunoprecipitation was performed per
instructions from Upstate using anti-Ovol1, anti-c-Myb
(Cat #sc-7874, Santa Cruz), anti-acetyl histone H3 (Cat #
06-599, Upstate) or anti-HDAC1 antibodies. The immu-
noprecipitates were analyzed by semi-quantitative PCR
using the following primer pairs: 2F: 50-GAAACCGG
TTCGACAGGTAAC-30 and 2R: 50-TTTCCAACTAC
GCCGAAGGTC-30; 1F: 50-ACTCACAGAGCTACACC
TGCCT-30 and 1R: 50-CATGTGTTCCTGGTCCTTGA
G-30. Select samples were also analyzed by real-time PCR
(data not shown). The PCR program used was: 948C,
1min, followed by 30–33 cycles of 948C, 45s; 608C, 45s;
728C, 1min and a ﬁnal extension at 728C for 7min.
The ChIP signal for a given primer pair was computed
as a ratio of the diﬀerence in PCR band intensity
between the speciﬁc antibody and control IgG over
the PCR band intensity of the input sample prior to
immunoprecipitation.
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Ovol1 binds toits own promoter
A thorough understanding of the DNA sequence deter-
minants of Ovol1 binding is an important prerequisite for
studies of its downstream targets and transcriptional
regulatory activity. Previous analysis of several mouse
genomic DNA sequences to which Ovol1 binds in vitro led
to the identiﬁcation of a CCGTTA sequence as a likely
Ovol1 recognition motif (9). To further deﬁne high-
aﬃnity Ovol1-binding consensus, we employed CASTing
(Cyclic Ampliﬁcation of Selected Targets), a non-biased,
in vitro site-selection approach. This analysis identiﬁed a
10-bp consensus sequence, A/TA/TA/TCC/TGTTAA/T,
that was bound by recombinant Ovol1 (Table 1).
This consensus strongly resembles the Drosophila OVO
recognition sequence ACMGTTACT (M¼A, C, T) (28).
While the core hexamer, CC/TGTTA, is almost identical
to the previously obtained motif, it is clear that
high-aﬃnity Ovol1 sites favor ﬂanking sequences that
are AT-rich.
To test the utility of our CASTing-identiﬁed consensus
and based on the ﬁnding that Drosophila ovo locus is auto-
regulatory (12,13), we searched the Ovol1 promoter for
presence of this consensus motif. Care was taken to look
for putative sites that have AT-rich ﬂanking sequences.
Two such sequences were found in the 700-bp Ovol1
promoter (1) (Figure 1A), both close to the transcription
start site (þ1), reminiscent of a key feature of the
Drosophila OVO-binding sites (29). The proximal site
(Ovol1D) is a better match to the consensus than the distal
one (Ovol1L), and consistently Ovol1D bound Ovol1 with
a higher apparent aﬃnity than Ovol1L (Figure 1B). The
speciﬁcity of the interaction was conﬁrmed by the
observation of a supershift of the Ovol1–DNA complex
when anti-Ovol1 antibody was added (lane 9, Figure 1B).
These results indicate that the sequence parameters
revealed by the CASTing analysis can be used to identify
bona ﬁde Ovol1-binding sites in natural promoters.
To further characterize the Ovol1–Ovol1 promoter
interaction, we performed two additional lines of experi-
ments. First, we generated recombinant proteins contain-
ing only the C-terminal (amino acids 107–267, including
the zinc ﬁnger domain) or the N-terminal half (amino
acids 1–107, lacking the zinc ﬁnger domain) of Ovol1
and tested their ability to bind to Ovol1D. The C-terminal
half retained the ability to bind but the N-terminal half
did not (Figure 1C), indicating that the DNA-binding
moiety of Ovol1 is the zinc ﬁnger domain. Second,
we performed footprinting experiments using a 370-bp
Ovol1 promoter fragment (corresponding to  356 to
þ15bp) encompassing both the proximal and distal
Ovol1-binding sites to determine the nucleotide contacts
of Ovol1 in a large sequence context. Under the
experimental conditions used, increasing concentrations
of recombinant Ovol1 created a single DNase I footprint
of  19bp encompassing the proximal but not the distal
site (in bracket) (Figure 1D). This result conﬁrms that
the proximal sequence constitutes a higher-aﬃnity site.
Hydroxyl radical, a small chemical reagent that cleaves
DNA in a base-independent manner, was next employed
to pinpoint the nucleotides within this region that
contact Ovol1. Footprinting with hydroxyl radical usually
provides a ﬁner mapping of protein–DNA contacts due to
the small size of the reagent and hence greater accessibility
to DNA. The result of this experiment conﬁrmed that
Ovol1 makes contacts with the core hexamer, CCGTTA
(Figure 1E), within the DNase I-footprinted region of the
Ovol1 promoter. In addition, a 5-bp sequence, GTTGT
(or CAACA, opposite strand, underlined in Figure 1E),
which is slightly upstream of the hexamer, was also
contacted by Ovol1. Together, these results identify the
Ovol1 promoter as a putative target of Ovol1 and provide
new insights into how Ovol1 interacts with DNA.
Ovol1 represses thetranscription ofits own promoter
in aDNA binding-dependent manner
We performed both in vivo and in vitro experiments to
examine whether Ovol1 regulates its own transcription.
Ovol1 knockout mice, in which exons 3 and 4 encoding the
C-terminal zinc ﬁnger region are deleted, produce no
detectable Ovol1 protein (1) but still generate aberrant,
high-molecular-weight transcripts (7). The ﬁrst two exons
of the gene as well as the upstream regulatory sequences
(including the Ovol1-binding sites identiﬁed above)
remain intact in these mutant animals, therefore allowing
us to compare the total level of transcripts generated
from the wild-type and mutant Ovol1 alleles to assess
auto-regulation. Northern blot analysis of skin RNAs
isolated from wild-type and Ovol1
 /  newborns and E16.5
embryos revealed signiﬁcantly higher transcript levels
in the mutant (Figure 2A and data not shown). This result
suggests that transcription from the Ovol1 locus is
up-regulated when Ovol1 protein is absent.
We next performed reporter assays to directly assess
the eﬀect of Ovol1 protein on Ovol1 promoter activity.
In 293T cells, a dosage-dependent repression of the
basal activity of the promoter by Ovol1 was observed
(Figure 2B). A similar repression was observed in
NIH3T3 cells, although there the basal promoter activity
was signiﬁcantly lower (data not shown). The repression
depended on the ability of Ovol1 to bind to DNA,
as mutating the cysteines in the ﬁrst three C2H2 zinc
Table 1. A weighted matrix to determine the Ovol1 consensus binding
site.
Position  3  2  11 2 3 456 7
(Percent Occurrence) A 46 43 51 22 10 0 6 0 72 33
(Percent Occurrence) C 7 11 8 56 46 0 16 0 8 11
(Percent Occurrence) G 18 15 10 3 0 100 0 2 12 17
(Percent Occurrence) T 29 31 31 19 44 0 78 98 8 39
Ovol1 Consensus site A/T A/T A/T C C/T G T T A A/T
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structure and hence DNA binding, completely
abolished repression (Figure 2B). A deletion of the
CCGTTA sequence (MutP-D) in Ovol1 promoter led to
a reduction in the extent of Ovol1 repression (Figure 2C),
indicating that this binding site is required to
mediate maximal repression. Surprisingly, a deletion of
the low-aﬃnity distal site (MutP-L) also led to reduced
repression. Moreover, a further reduction was observed
when both sites were deleted (MutP-LD), suggesting
an additive eﬀect. Therefore, inside the cells both the
high- and low-aﬃnity sites are utilized for repression.
Collectively, these studies, while indicative of a somewhat
promiscuous nature of DNA sequence recognition of
Ovol1 within cells, demonstrate that Ovol1 represses
the basal transcription of Ovol1 promoter by directly
binding to it.
Ovol1 competes withc-Myb forDNA binding and
represses c-Myb-activated transcription
Interestingly, the CCGTTA sequence to which Ovol1
binds is identical to the high-aﬃnity binding site
of c-Myb, a proto-oncoprotein and transcription activator
(23,30–33). This ﬁnding raises the possibility that Ovol1
Figure 1. Ovol1 binds to its own promoter and binding requires the zinc ﬁnger domain. (A) Organization of the Ovol1 promoter showing the
positions of the proximal (Ovol1D) and distal (Ovol1L) sites, with their sequences shown below the stick diagram. The transcription start site is þ1.
Also indicated are the positions of primer sets 1 and 2 used for ChIP assays (see below). (B) Results of EMSA assays showing binding of
recombinant Ovol1 to CCGTTA-containing oligonucleotides Ovol1L (left) and Ovol1D (right). Left panel: lane 1, free probe, lanes 2–4,
with increasing amounts (172–688nM) of recombinant His6–Ovol1. Right panel: lanes 1 and 7, free probe; lanes 2–6, with increasing concentrations,
(50–431nM) of recombinant His6–Ovol1; lanes 8 and 9, with 156nM recombinant His6–Ovol1 and with and without anti-Ovol1 antibody,
respectively. Arrowhead and arrow represent Ovol1–DNA and Ovol1–DNA–antibody complexes, respectively. (C) Results of EMSA assays on
Ovol1D using recombinant full-length and truncated Ovol1 proteins. Oval and arrowhead represent full-length and C-terminal Ovol1–DNA
complexes, respectively. Lower bands (indicated by *) are likely due to incompletely translated protein products. (D) DNase1 footprint of the
Ovol1 promoter. The sequence of the footprinted region ( 53 to  35) is indicated on the right. The bracket on the left indicates the position
of the low-aﬃnity site which is present within the oligonucleotide Ovol1L.( E) Densitometer tracing of hydroxyl radical footprint of the
Ovol1 promoter, with the footprinted nucleotides underlined and its position indicated.
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DNA binding. This biochemical model is consistent
with the growth inhibitory function of Ovol1 and a role
for c-Myb in maintaining immature, proliferating cells of
the hematopoeitic and possibly epithelial lineages (23,34).
To test this model, we ﬁrst examined whether recombi-
nant Ovol1 binds to previously reported c-Myb cognate
sequences. Oligonucleotide mim-A contains a CCGTTA
motif and hence is a high-aﬃnity c-Myb site, whereas
mim-C represents a low-aﬃnity c-Myb site (32). In EMSA
assays, recombinant Ovol1 bound to mim-A but not
mim-C (Figure 3A). We next tested whether Ovol1
competes with c-Myb for binding to mim-A. The addition
of increasing concentrations of recombinant Ovol1 at a
ﬁxed concentration of c-Myb resulted in a gradual
decrease in the amount of c-Myb–DNA complexes
and a concomitant increase in slow-migrating
complexes, the mobility of which are consistent
with that of Ovol1–DNA complexes (Figure 3B,
lanes 1–5, and data not shown). The addition of anti-
Ovol1 antibody led to a supershift of the Ovol1–DNA
complexes and reappearance of the c-Myb–DNA
complexes. We also found that c-Myb was able to
bind to Ovol1D, an Ovol1 cognate sequence as shown
above, and that recombinant Ovol1 competed away this
binding (data not shown). Taken together, these
results suggest that Ovol1 and c-Myb recognize similar
DNA sequences, namely a CCGTTA motif, and
that in vitro, Ovol1 is able to compete with c-Myb for
binding to this motif.
To determine if competition for DNA binding also
occurs within cells at the endogenous Ovol1 promoter in
its chromatin context, we performed chromatin immuno-
precipitation (ChIP) assays on cells transfected with either
c-Myb expression construct alone or both c-Myb and
Ovol1 expression constructs. NIH3T3 cells instead of
293T cells were used for these experiments because they
do not express any detectable levels of endogenous
Ovol1 protein (data not shown), therefore allowing
us to determine the competition eﬀect of ectopically
expressed Ovol1. When only c-Myb was present, we
detected c-Myb occupancy at the Ovol1 promoter in
a region that contains the Ovol1/c-Myb-binding sites
identiﬁed in vitro (ampliﬁed by primer set 2, the position
of which is indicated in Figure 1A), but not the control
region that is 2kb upstream (ampliﬁed by primer set 1)
(Figure 3C). When Ovol1 was introduced, however,
Ovol1 but not c-Myb now occupied the Ovol1 promoter.
This result demonstrates that Ovol1, when present,
displaces c-Myb from the Ovol1/c-Myb-binding sites in
the endogenous Ovol1 promoter. In contrast to wild-type
Ovol1, the DNA-binding mutant, ZnFC2A, did not
eﬃciently displace c-Myb, indicating that this ability to
compete away c-Myb binding requires the DNA-binding
ability of Ovol1.
The binding of c-Myb to Ovol1 promoter raises the
issue of whether c-Myb activates this promoter, since
c-Myb is known to be a transcriptional activator (23).
In reporter assays, c-Myb indeed activated the Ovol1
promoter in a dosage-dependent manner (Figure 3D).
Moreover, maximum activation was dependent on both
the proximal CCGTTA-containing and the distal low-
aﬃnity Ovol1-binding sites (Figure 3D and data not
shown). Thus, within cells, c-Myb displays identical
and similarly promiscuous DNA sequence preferences
as Ovol1 (see Discussion), but shows opposite transcrip-
tional regulatory activity. To elucidate the functional
consequence of Ovol1 competition with c-Myb, we set
out to determine if Ovol1 represses c-Myb-activated
promoter activity. Transient transfection experiments
were performed using a ﬁxed concentration (50ng)
of the c-Myb expression construct (where a  2-fold
Figure 2. Ovol1 represses its own transcription. (A) Results of northern blot analysis of E16.5 wild-type and Ovol1
 /  skin. The Ovol1 probe
detects transcripts of expected sizes in the wild type (7). The bracket indicates high-molecular-weight gene products of the mutant Ovol1 locus.
The level of GAPDH serves as a loading control. Multiple embryos per genotype were examined and representative results are shown.
(B) Ovol1 represses Ovol1 promoter in a DNA binding-dependent manner. The exact mutations made in ZnFC2A are indicated. Concentrations
of expression constructs are: Ovol1—0.7, 1.3, 2.5 and 5ng; ZnFC2A—5, 10, 15, and 20ng. (C) Ovol1 repression of the Ovol1 promoter requires
both the proximal and distal sites. The sequences of wild-type and mutant promoters are as indicated at the top.
1692 Nucleic Acids Research, 2007, Vol. 35, No. 5activation was seen) and increasing concentrations of
the Ovol1 expression construct. A dosage-dependent
repression was observed; at high concentrations
Ovol1 repressed the promoter to a level that is
well below the basal activity (Figure 3E). When
ZnFC2A was used instead of the wild type, a complete
loss of repression was observed. Therefore, Ovol1
represses both basal and c-Myb-activated transcription
of the Ovol1 promoter, and at least one underlying
mechanism of this repression is the displacement of c-Myb
from its cognate sites, thereby antagonizing c-Myb
activation.
Ovol1 represses basal and activated transcription of
theOvol1 promoter by recruiting HDAC activity
viaits SNAG domain
Sequence analysis of the Ovol1 protein revealed the
presence of an N-terminal 9-amino acid SNAG domain
(Figure 4A), which was ﬁrst identiﬁed in proto-oncopro-
tein Gﬁ-1 and vertebrate Snail-related proteins (9).
Since the SNAG domain has been functionally implicated
in recruiting HDAC1 and –2 (35,36), we hypothesized
that Ovol1 may also repress transcription actively,
namely by recruiting HDAC co-repressors. A generally
accepted criterion for an active repressor is that it can
repress transcription independently of its own DNA
recognition context (37). Indeed, Ovol1 when fused to a
Gal4 DNA-binding domain (Gal4DBD) was able to
repress the Gal-tk promoter, where the minimum tk
promoter is under the control of multimerized Gal4-
binding sites (38), whereas GalDBD alone had no eﬀect
(Figure 4A and data not shown). Subsequent deletion
studies mapped the repression domain to an N-terminal
45-amino-acid region encompassing the SNAG domain
(data not shown). To determine if the SNAG domain is
indeed required for auto-repression, we generated
untagged Ovol1 mutant derivatives containing deletion
of (15 and 6SNAG), or a point mutation (P2ASNAG)
in SNAG, and assayed their repressor activity on the
Ovol1 promoter. These mutations led to a complete loss of
repression, while the wild-type protein of comparable
expression levels repressed eﬃciently (Figure 4B).
These results indicate that SNAG is essential for Ovol1
repression of the basal activity of Ovol1 promoter.
It is unlikely that the SNAG in Ovol1 is involved in
DNA binding or nuclear localization, as we have shown
that the N-terminal half of Ovol1 is dispensable for DNA
binding (see above), and that 15 was properly localized
to the cell nuclei (data not shown).
We next directly investigated whether Ovol1 repression
of its own promoter is HDAC-dependent. As observed in
Figure 4C, TSA treatment did not signiﬁcantly aﬀect the
basal activity of Ovol1 promoter but led to a signiﬁcant
reduction ( 4-fold) in repression by Ovol1. Having
established that Ovol1 repression requires HDAC activity,
we next performed immmunoprecipitation (IP) assays to
determine if Ovol1 interacts with HDACs. Indeed, Ovol1
protein was immunoprecipitated from extracts of 293T
cells transfected with Flag-tagged HDAC1 by an anti-
Flag antibody, but not by the appropriate IgG control
(Figure 4D). Conversely, anti-Ovol1 antibody but not the
relevant IgG control immunoprecipitated both exogen-
ously and endogenously expressed HDAC1. In contrast,
the anti-Flag antibody did not eﬃciently immunoprecipi-
tate the 15 protein that lacks the SNAG domain.
Therefore, the SNAG domain, which mediates maximum
Ovol1 repression, is also required for its optimum
Figure 3. Ovol1 competes with c-Myb for DNA binding and represses
c-Myb-activated promoter activity. (A) Results of EMSA assays
showing that Ovol1 binds to c-Myb cognate site mim-A but not
mim-C (for oligonucleotide sequences, see Materials and Methods). ‘-’,
no protein. . represents increasing concentrations (216–650nM) of
recombinant Ovol1 protein. (B) Ovol1 competes with c-Myb for
in vitro interaction with mim-A. Lane 1, free probe; lane 2, 0.8mgo f
c-Myb bacterial extract; lanes 3–6, 0.8mg c-Myb extract and increasing
concentrations (31–188nM) of recombinant Ovol1 protein; lane 7,
0.8mg c-Myb extractþrecombinant Ovol1 (188nM)þanti-Ovol1
antibody. Oval, arrowhead and arrow represent c-Myb–DNA,
Ovol1–DNA and Ovol1–DNA–antibody complexes, respectively.
(C) Results of ChIP assays showing that Ovol1 competes with c-Myb
for binding to the endogenous Ovol1 promoter. Equivalent levels
of Ovol1 and ZnFC2A proteins were expressed (data not shown).
(D) c-Myb activates the Ovol1 promoter in an Ovol1-binding
site-dependent manner. (E) Ovol1 represses c-Myb-activated Ovol1
promoter activity in a DNA binding-dependent manner.
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observed interaction of Ovol1 with HDAC2 and  3,
no apparent interaction with the mSin3A co-repressor was
detected (Figure 4E and data not shown). This ﬁnding
is distinct from those made for Snail (35), suggesting
that while the SNAG domain in both Ovol1 and
Snail proteins is involved in interaction with HDAC
co-repressor complexes, the exact nature/composition of
the complexes is protein speciﬁc. To further demonstrate
a functional involvement of HDACs in Ovol1 repression,
we co-transfected increasing amounts of an HDAC1
expression plasmid along with the Ovol1 expression
construct. Indeed, an HDAC1 dosage-dependent
enhancement of promoter repression was observed
(Figure 4F). This enhancement required the presence of
Ovol1, suggesting that HDAC1 is recruited to the
promoter via Ovol1.
We next performed ChIP assays to directly examine the
recruitment of HDAC1 by Ovol1 to the promoter in its
genomic context. Consistent with the results described
above, both wild-type and 15 Ovol1 proteins were
recruited to the Ovol1 promoter in a region that contains
the Ovol1-binding sites, whereas no association was
observed in the control region (Figure 4G). However,
HDAC1 occupied the same region only when wild-type
Ovol1 was present. These results indicate that HDAC1 is
recruited to Ovol1 sites that are present in the genomic
Ovol1 locus, and that the SNAG domain of Ovol1 is
responsible for HDAC1 recruitment. Collectively, our
studies provide strong evidence that Ovol1 is able to
actively repress the transcription of Ovol1 promoter, likely
by recruiting HDAC activity to its target sites.
To address the relative contribution of passive and
active repression mechanisms in c-Myb-activated tran-
scription, we compared the dosage eﬀect of wild-type and
15 Ovol1. Since 15 is deﬁcient in HDAC1 interaction
but is able to bind DNA, we predicted that its repression
of the Ovol1 promoter is indicative of the extent of passive
repression, and would therefore be less dramatic than the
wild type. Indeed, at high concentrations, wild-type Ovol1
repressed c-Myb-activated transcription to an extent that
is below the basal level, whereas 15 was only able to
bring the promoter activity back down to the basal level
(Figure 4H). This result suggests that Ovol1 not only
displaces c-Myb to release activation, but also recruits
HDAC activity to bring about additional repression at the
same time. Therefore, Ovol1 combines passive and active
repression mechanisms to achieve maximum repression of
the Ovol1 promoter.
Ovol1 and c-Myb exert opposing effects on histone H3
acetylation atthe Ovol1 promoter
HDACs repress transcription by deacetylating histone
tails at the target promoter, whereas c-Myb is known to
activate transcription by acetylating histones at its target
promoters via interaction with the histone acetyl transfer-
ase (HAT) p300 (39). We therefore hypothesized that the
Figure 4. Ovol1 repression requires the SNAG domain and its HDAC interaction. (A) Ovol1 represses transcription when tethered to heterologous
DNA. (B) Disruption of the SNAG domain abolishes Ovol1 repression of its own promoter. P, promoter only. 15, a truncated protein lacking the
ﬁrst 15 amino acids including the SNAG domain. 6SNAG, a protein where six of the nine core amino acids of SNAG are deleted. P2ASNAG,
a protein where the highly conserved proline residue at position 2 (22) is replaced by an alanine. (C) Reduced repression upon TSA treatment
suggests that Ovol1-mediated repression is HDAC-dependent. The numeric values above the bars represent the actual extent of repression by Ovol1
in the absence (control) or presence of TSA. (D) Ovol1 interacts with HDAC1 via its SNAG domain. The antibodies (Ab) used for IP and Western
are indicated on the right. IgG, control immunoglobulin. (E) Ovol1 interacts with HDAC2 and  3. (F) HDAC1 augments Ovol1-mediated
repression of the Ovol1 promoter. (G) Results of ChIP assays revealing Ovol1 and HDAC1 occupancy at the endogenous Ovol1 promoter in
a region containing Ovol1-binding sites. For positions of primer sets, see Figure 1A. (H) Inability of Ovol1 to interact with HDAC1 (15) results
in compromised repression of c-Myb-activated transcription.
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to a HAT-HDAC switch, thereby resulting in a deacety-
lated chromatin to silence gene expression. To test this
model, we examined if changes in Ovol1 and c-Myb
occupancy aﬀects histone H3 acetylation at the Ovol1
promoter. Upon transfection with c-Myb, a slight but
reproducible increase in H3 acetylation was detected in
the region that contains Ovol1/c-Myb-binding sites
(Figure 5A and B), supporting the previous report
that c-Myb facilitates H3 acetylation at its target
promoter (39). In contrast, when Ovol1 alone was
transfected, a reduction in H3 acetylation was seen,
and the reduction depended on the presence of the ﬁrst 15
amino acids of the protein (Figure 5A). Based on this
result and studies presented above, we surmise that the
SNAG domain is a key in recruiting HDAC1, which in
turn deacetylates histone H3 at the target chromatin.
When Ovol1 and c-Myb were co-introduced, the level of
acetylated H3at the promoter was now signiﬁcantly lower
than that with only c-Myb, and was comparable to that
with only Ovol1 (Figure 5A and B). Co-introduction
of ZnFC2A with c-Myb however, failed to reduce the
c-Myb-enhanced H3 acetylation, indicating that binding
of Ovol1 to the promoter is required for the observed
reduction in histone acetylation levels. These diﬀerences
between various conditions were reproducible and
statistically signiﬁcant. In all experiments, no change in
H3 acetylation of the control region was observed
(data not shown). Collectively, our data suggest that in
cells, Ovol1 not only displaces c-Myb, hence decreasing
c-Myb-facilitated histone acetylation, but also recruits
HDAC activity to decrease the basal level of histone
acetylation at the promoter.
DISCUSSION
Auto-regulation is a well-known mechanism to intricately
regulate the concentration of developmentally important
transcription factors, and known examples include Snail1
and Gﬁ-1B repressors (40–43). The idea of a negative
auto-regulation of Ovol1 is supported by our in vivo
studies detecting increased levels of Ovol1 transcripts in
tissues where Ovol1 protein production is ablated, and
by our in vitro studies that Ovol1 binds to and represses its
own promoter. Our study, in light of previous reports
on Drosophila ovo (12,13), suggests that auto-regulation
is an evolutionarily conserved aspect of Drosophila and
mouse ovo genes.
To date, studies on ovo genes have focused on their
biological function and genetic context. Our work is the
ﬁrst to probe into the biochemical mechanisms by which
this family of zinc ﬁnger proteins regulates transcription.
Our results demonstrate that Ovol1 represses basal
transcription in a manner that depends on its N-terminal
SNAG moiety. The SNAG domain is found in multiple
transcriptional repressors, where both its sequence and
position are conserved (36,44). Our result that SNAG
is important for Ovol1 repression is consistent with
previous reports demonstrating a functional involvement
of SNAG in other repressors including Gﬁ-1 and Snail
(35,36). The N-terminal location of the SNAG domain
is likely important for its repressive function, as Ovol1
protein tagged at the N-terminus does not repress as well
as the untagged protein (data not shown). Ovol1 is also
capable of repressing activated transcription by compet-
ing with the c-Myb activator for binding to common
DNA sites. Taken together, our data suggest a novel
model where Ovol1 uses an active repression mechanism
to repress basal transcription of its promoter, and uses
both passive and active repression mechanisms in
combination to exert maximum repression of c-Myb-
activated transcription (Figure 6). A functional outcome
of the c-Myb-Ovol1 switch at the target promoter is the
change from an acetylated, presumably open chromatin,
to a deacetylated, presumably condensed chromatin,
resulting in silencing of target gene expression. Although
not proven, dual (active and passive) repression has been
implicated for vertebrate members of the Snail family
of zinc ﬁnger repressors, which are involved in important
developmental processes such as mesoderm and neural
crest formation [reviewed in (44)]. While a SNAG domain
is found in all vertebrate but not the Drosophila members
of the Snail protein family (36), a domain bearing
resemblance to SNAG consensus is present at the
N-termini of mouse Ovol2, human Ovol1 and Ovol2,
as well as Drosophila Svb, an epidermis-speciﬁc Ovo
protein isoform (45). The signiﬁcance of this domain
in the biochemical activities of these other Ovo proteins
remains to be addressed. The similarity between Ovol1
and Snail1 repressors in auto-regulation and mode of
repression is intriguing. In fact, Ovol1 shares a 28%
sequence identity (39% similarity) (including SNAG
domain) with the mouse Snail1 protein. A negative
feedback loop to self-limit expression and dual repression
to ensure an eﬃcient, activation-silencing switch might be
Figure 5. Opposing eﬀects of Ovol1 and c-Myb on histone H3
acetylation at the endogenous Ovol1 promoter. (A) Results of ChIP
assays showing that c-Myb and Ovol1 occupancy correlates with
increased and decreased respectively histone H3 acetylation from the
basal level. (B) Results of quantiﬁcation of ChIP signals. Error bars
were calculated from three independent PCR reactions of a single
immunoprecipitate, and results are representative of multiple ChIP
experiments. ‘*’ indicates statistically signiﬁcant (P50.003) diﬀerence
from the untransfected sample.
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regulate cell fates at important crossroads such as
proliferation and terminal diﬀerentiation.
In addition to HDAC1, Ovol1 also interacts with
two other Class I HDACs, HDAC2 and -3, but not with
co-repressor mSin3A. This diﬀers from previous studies
on Snail, where the SNAG domain interacts with
HDAC1, -2 and mSin3A but not HDAC3 (35).
It has been suggested that the Snail protein might
assemble both mSin3A-dependent and -independent
co-repressor complexes (35). Our studies on Ovol1 provide
yet another possibility for SNAG-mediated complex
formation, and extend our understanding of the repertoire
of HDAC-containing co-repressor complexes. This work
now adds Ovol1 to the list of versatile transcriptional
repressors that can repress transcription in multiple ways.
We have recently shown that Ovol1 represses c-Myc
and Id2 transcription by binding to their promoters (8,9).
c-Myc is a known target of c-Myb (46–48), and our
DNA-binding studies have shown that c-Myb indeed
binds to an Ovol1 site in the Id2 promoter (data not
shown). Therefore, the passive and active repression
mechanisms of Ovol1 discovered here may apply to
Ovol1-mediated regulation of its other target genes.
In addition to discovering the CCGTTA-containing
high-aﬃnity site, this article and our previous work also
identiﬁed atypical Ovol1-responsive elements that show
low-binding aﬃnity in vitro but are utilized inside cells (9).
This extends the parallel with c-Myb, as it was previously
reported that low-aﬃnity c-Myb-binding sites are indeed
functionally utilized (46,47). Alternative mechanisms
such as assistance from auxiliary factors might exist to
recruit the proteins to these sites in vivo. Systematic ChIP-
on-chip analysis of Ovol1 binding in vivo might reveal
additional atypical sites and shed light on the underlying
mechanisms. The discovery of competition between Ovol1
and c-Myb in DNA binding and transcriptional regulation
is particularly exciting in light of their apparently
opposing biological functions. c-Myb positively regulates
the proliferation of immature cells that are committed
to diﬀerentiation (23), while Ovol1 is expressed later in
a diﬀerentiation pathway and is necessary for eﬃcient
proliferation arrest (7–9,15). Based on the data presented
here, it is tempting to speculate that c-Myb and Ovol1
transcriptional regulation represent two consecutive steps
in a relevant diﬀerentiation pathway, where the balance
of the opposing eﬀects of these two proteins coordinates
proliferation with diﬀerentiation. Since c-Myb is expressed
in proliferating epidermal cells (34), a possible scenario
in skin epidermis is that c-Myb activates genes such as
c-Myc and Id2 to up-regulate the transient proliferation of
progenitor cells that have committed to diﬀerentiate, but
also turns on the expression of its own antagonist, Ovol1,
to restrict proliferation to allow terminal diﬀerentiation
to actually occur. This notion can now be tested using
a keratinocyte diﬀerentiation as well as animal models.
Since c-Myb knockout mice die during gestation prior
to the onset of epidermal diﬀerentiation, a study of an
epidermal involvement of c-Myb awaits the generation
of a conditional allele.
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